Latest news with #JAZZ
Business Wire
15-07-2025
- Business
- Business Wire
IMPLANET Announces CFDA Approval for Its Innovative JAZZ Range in China
BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, PEA-PME eligible), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, today announced that its innovative JAZZ range has been approved by the CFDA in China. As part of a distribution partnership signed in November 2022, IMPLANET and Sanyou Medical have successfully registered the JAZZ range, dedicated to tape fixation in the treatment of spinal pathologies, on the Chinese market, the world's largest potential market in terms of volume. This is a major milestone in the strategic partnership with Sanyou Medical. The JAZZ system can be used in combination with the full range of spinal fixation systems already developed by Sanyou Medical, offering Chinese surgeons a complete hybrid surgical solution that is unique in this market. Ludovic Lastennet, CEO of IMPLANET, said: "Obtaining the registration certificates for our JAZZ range from the CFDA, the Chinese health authority, marks a major new turning point for Implanet, and once again attests to the high clinical value of our JAZZ ® technology. Penetration of the Chinese market, through our alliance with SanYou Medical, has been at the heart of our strategy since 2022. SanYou Medical's marketing and commercial strength in China should rapidly provide Implanet with new resources to accelerate its development in one of the world's most important markets. This partnership also demonstrates our ability to develop disruptive technologies that meet the need for innovation in new markets. It is fully in line with our medium-term strategic development plan, based both on the deployment of our direct sales model in France, the United States and high-potential European markets, and on the development of strategic partnerships with major players. We are now working on the commercial launch, which should take place early in the fourth quarter of this year". Strategy and Outlook for 2025 Finalize the registration of existing products under the European Medical Device Regulation (MDR) and the FDA's 510(k). Continue to expand the Company's presence in the United States: Reinforce resources and commercial capabilities for the historical team; Expand the Company's direct approach by enlarging the scientific team of key opinion leaders; Enhance market momentum and expand the product offering: Deploy the commercial and technological partnership with Sanyou Medical for the joint development of a new, innovative European range of hybrid posterior fixation systems; Launch distribution of the JAZZ ® platform in China, the world's largest spine market by volume, in collaboration with Sanyou Medical; Distribute advanced medical technology equipment in Europe, including the ultrasonic surgical scalpel from SMTP Technology Co. Position Implanet as a partner for surgeons and healthcare institutions in terms of Artificial Intelligence and robotics adapted to our implants. Upcoming Financial Communications First Half 2025 results – September 16 th, 2025, after market close About IMPLANET IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery and distributes medical technology equipment. Its activities focus on an innovative solution to improve the treatment of spinal pathologies (JAZZ ®), complemented by the product range of thoraco-lumbar screws, cages, and cervical plates, acquired through Orthopaedic & Spine Development (OSD) in May 2021. In 2022, the Company entered into a commercial, technological, and financial partnership with Sanyou Medical, China's second-largest medical device manufacturer. As part of this strategic agreement, IMPLANET developed in 2024 the Jazz Spinal System™ hybrid fixation system, a unique new range featuring a comprehensive pedicle screw solution, combined with the market's most advanced braided implant technology, JAZZ ®. IMPLANET's orthopedic platform is built on the traceability of its products. Protected by four families of international patents, JAZZ ® has received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA), CE marking in Europe, and ANVISA approval in Brazil. IMPLANET employs 46 people and generated €9.4 million in consolidated revenue in 2024. Based near Bordeaux, France, IMPLANET has operated a U.S. subsidiary in Boston since 2013. IMPLANET is listed on the Euronext Growth market in Paris. For more information, visit
North Wales Live
22-06-2025
- Entertainment
- North Wales Live
Summer cocktails: 29 delicious drinks to enjoy in the sun
Summer is well and truly here and we're now braced for months of scorching temperatures while enjoying cooling drinks in the garden. But if you find yourself getting bored with the usual lager or G&T, we have some amazing cocktail recipe ideas for you to spice things up with. Be that fab floats or powerful punches, there are drinks here to suit everyone - and the best thing is you don't need a PhD in mixology to rustle one up. Although we suggest you keep quiet and enjoy all the plaudits! Spiced Pineapple Daquiri 50ml Salford Spiced Pineapple Rum 12.5ml Velvet Falernum 25ml Lime Juice 25ml Pineapple Juice 12.5ml Sugar Syrup Method: Hard shake with cubes of ice and fine strain into a coupe glass. Garnish with 3 drops of Angostura Bitters, serve and enjoy. Apple & Raspberry Wine Spritzer 100ml white wine 50ml JAZZ Apple juice Soda water to top (approx. 50ml) 4 raspberries Apple fan to garnish Method: Add the raspberries to a glass and muddle. Fill with ice and pour over the white wine and the apple juice. Stir gently to combine and then top with soda water and garnish with an apple fan. Dark 'n Stormy Granita 1 can of Goslings Ginger Beer 50ml Goslings Black Seal Rum Method: Pour you can of Goslings ginger ale into a freezer proof container and freeze for three hours. Every 30 minutes, go back and break up the ice. Add to the slushy to a glass and tip the Goslings Black Seal rum on top. Garnish with a slice of lime. Spicy Margarita Method: Mix ingredients and then garnish with slice of lime or salt rim. Gin & Tonic Float 50ml Hernö Old Tom Gin 100ml Tonic Water 1 Scoop Raspberry Ripple Ice Cream Method: Add the gin and tonic to a large glass (wine or rocks) and stir to combine. Top with a scoop of raspberry ripple ice cream. Gin Martini 60ml No. 3 London Dry Gin 10ml dry vermouth 1 lemon Method: Stir over ice in a mixing glass and strain into a chilled Martini glass. Garnish with a lemon twist. Iced Tea Rum Punch (jug) 150ml Goslings Black Seal Rum 100ml Lime Juice 100ml Pineapple Juice 50ml Lemon juice 100ml Simple Syrup 400ml Freshly Brewed Black Tea 4 drops of The Bitter Truth – Old Time Aromatic Bitters Ice Method: Brew black tea and allow to cool. To a jug, add all the other ingredients and stir. Garnish with lime and pineapple and serve. Sumer Rum Picoso Method: Mix ingredients and ass a slice of red chilli or lime, or add a dash of grenadine to give a nice colour gradient. Count Negroni's Punch (Serves 6-8) 200ml Bathtub Gin 100ml Campari 100ml sweet vermouth 500ml blood orange soda, chilled Clementines, sliced Bundt cake tin Method: To make your retro ice ring, slice a few clementines and add to your bundt pan. Fill with water and freeze overnight. In a large punch bowl or jug, combine the Bathtub Gin, Campari, and sweet vermouth. Stir well to ensure all ingredients are fully mixed and chill the mixture in the refrigerator for at least 1-2 hours to allow the flavours to meld together. Just before serving, add your ice ring to the punch bowl to keep the mixture cold. Top off the punch with chilled blood orange soda, stirring gently to combine. Earl Grey Ice Tea 45ml Hernö London Dry Gin 60ml freshly brewed Earl Grey tea, chilled 10ml lemon juice 1tsp sugar, to taste Lemon wheel, for garnish Method: Add all the ingredients to a mixing jug and stir well to combine. Check for sweetness and then strain into an old fashioned glass over a large ice cube. Garnish with a lemon wheel. Summer Smokey Spicy Mazcalita Method: Mix ingredients and then garnish with a red chilli/slice of lime or tajin rim. Kombucha, Peach & Mint Fizz (makes a pitcher) 100ml Hernö Old Tom Gin 600ml Sparkling Kombucha 4 Peaches Small bunch of mint Garnish Peach Slice Mint Sprig Method: Cut the peaches into segments and add to a pitcher. Add the mint (reserving some for garnish) and muddle until the peaches are thoroughly crushed. Pour in the gin and kombucha, top with ice, then stir well to combine. Place a peach segment and a mint sprig into four rocks glasses, followed by a large ice cube, then pour the cocktail into the glasses. Dark 'n Stormy Ice Cream Float Cocktail One scoop of Dark 'n Stormy ice cream 50 ml of Golsings Gold Seal Rum Ginger beer Candied lime Method: Make the ice cream by allowing some of the best vanilla ice cream you can find to soften. Add chopped crystalized ginger and Gosling's Black Seal Rum and blend it all in. Re-freeze and serve when ready. For the cocktail, add ice cream to a large milk shake glass. Add and then slowly pour ginger beer and rum on top. Decorate with a slice of candied lime. Negroni Gin 30ml No.3 London Dry Gin 30ml Gran Classico bitters or Campari 30ml Sweet Vermouth 1 orange ice Method: Combine the ingredients in a mixing glass and stir over ice until suitably chilled. Strain over fresh ice in a rocks glass and garnish with an orange twist. Piña Co-Lager 50ml Goslings Gold Seal Rum 330ml Einstök White Ale 200ml Pineapple Juice 50ml Coconut Water Garnish Pineapple Leaves Method: Pour the rum, pineapple juice and coconut water into a large stein or tankard. Add a handful of ice and mix to combine. Top with the Einstök White Ale. Garnish with three pineapple leaves. The ST-GERMAIN Hugo Spritz 45 ml ST~GERMAIN Elderflower Liqueur 60 ml Martini Prosecco 60 ml Soda Water 8-10 Mint Leaves Lime wedge for garnish Mint sprig for garnish Method: Add ice into a wine glass. Pour ST-GERMAIN and top with sparkling wine and soda water. Stir the drink to combine all the ingredients. Garnish with a mint sprig and lime wedge. Raspberry & Rosemary Gin Spritz (makes 2) 100ml Hernö Old Tom Gin 200ml Sparkling Wine 8 Raspberries 2 Sprigs Rosemary 4 Raspberries Method: Divide the raspberries between two Champagne flutes. Muddle until thoroughly crushed, then top with sparkling wine. Garnish each cocktail with a rosemary sprig and two raspberries. Five Farms Baby Lager 25ml cinnamon-flavoured whiskey (or Spanish liqueur for a sweeter taste) 15ml Five Farms Irish Cream Liqueur Method: Pour your whiskey or liqueur carefully into a glass, making sure not splash up the sides. Grab a spoon, Hold it upside down, just above the surface of the whiskey, and pour the Five Farms onto the spoon so that is floats across the top. St James's Spritz 35ml No.3 London Dry Gin 15ml elderflower cordial 125ml crémant 1 rosemary sprig 1 pink grapefruit Ice Method: Fill your wine glass with ice, add the ingredients, stir gently and top with a little more crémant. Garnish with a pink grapefruit slice and a sprig of rosemary. Desi Mango Gimlet 45ml Desi Daru Mango Vodka 15ml Cocchi Americano 15ml Coriander Seed Cordial Method: Stir all ingredients with ice until well-chilled. Strain into a chilled coupe glass. Express orange zest over the drink and discard. Rumango Kiwi Punch 1 cup Goslings Black Seal Rum 2 cups of mango nectar The juice from one JAZZ Apple 4 kiwi fruits (green or golden) ½ cup White Heron British Cassis 2 limes Ice Mint leaves Method: Peel the kiwi fruits and cut two in cubes and smash the other two in the bottom of a jug with a few mint leaves. Next add the cubes of kiwi along with one of the limes which has been sliced. Juice the other lime and add to the jug. Next add the Goslings Black Seal rum, the mango nectar and British Cassis before mixing well and then chilling. When ready to serve, add ice to the jug to refresh and serve in a Nick and Nora glass or wine glass. Orchard Garden Punch (Serves 6-8) 200ml Bathtub Gin 100ml elderflower cordial 500ml cloudy apple juice, chilled 100ml freshly squeezed lemon juice (about 2-3 lemons) 60ml agave syrup (adjust to taste) 500ml sparkling water or soda water, chilled Fresh mint leaves, thin slices of apple, and lemon slices for garnish Ice cubes Method: In a large punch bowl or jug, combine the Bathtub Gin, elderflower cordial, apple juice, freshly squeezed lemon juice, and agave syrup. Stir well to ensure all ingredients are fully mixed. Chill the punch in the refrigerator for at least 1-2 hours to allow the flavours to meld together. Just before serving, add ice cubes to the punch bowl to keep the mixture cold. Top off the punch with chilled sparkling water or soda water, stirring gently to combine. Garnish the punch with fresh mint leaves, thin slices of apple, and lemon slices. Desi Mango Soda 50ml Desi Daru Alphonso Mango Vodka 100ml Soda Water Method: Build over ice in a highball glass. Stir gently and garnish with a lime wedge. Summer Fruit Daiquiri (makes 2) 100ml Goslings Gold Seal Rum 250ml Summer Fruit Puree 1 Lime Fresh Raspberry Fresh Blackberry Method: Squeeze the juice of 1 lime into a cocktail shaker. Fill with ice, then add the rum and summer fruit puree. Shake until well combined, then pour into chilled coupe/margarita glasses. Garnish each cocktail with a fresh raspberry and a fresh blackberry. Sorrento Sunset Punch (Serves 6-8) 200ml Bathtub Gin Grapefruit & Rosemary 100ml Luxardo Bitter Bianco 500ml freshly squeezed grapefruit juice (about 3-4 large grapefruits) 60ml freshly squeezed lemon juice (about 2 lemons) 60ml agave syrup (adjust to taste) 500ml sparkling water or soda water, chilled Grapefruit slices and rosemary sprigs, for garnish Ice cubes Method: In a large punch bowl or jug, combine the Bathtub Gin, Luxardo Bitter Bianco, freshly squeezed grapefruit juice, freshly squeezed lemon juice, and agave syrup. Stir well to ensure all ingredients are fully mixed. Chill the punch in the refrigerator for at least 1-2 hours to allow the flavours to meld together. Just before serving, add ice cubes to the punch bowl to keep the mixture cold. Top off the punch with chilled sparkling water or soda water, stirring gently to combine. Garnish the punch with thin slices of grapefruit and sprigs of fresh rosemary. Spicy Mango Desi-rita 50ml Desi Daru Mango Vodka 20ml Triple Sec 5ml Agave Syrup 25ml Fresh Lime Juice ½ Fresh Chilli (of choice) Method: Muddle chili in a shaker. Add remaining ingredients with ice and shake vigorously. Fine strain into a glass rimmed with Achari Masala Salt. Summer Rummer Pitcher 100ml Goslings Black Seal Rum 300g frozen summer fruits 4 JAZZ apples (juiced) 350ml Prosecco to top Method: Take the frozen summer fruits straight from the freezer and blend with a JAZZ apple juice until you have a smoothie-like consistency. Add ice to a 1 litre or 1 ½ litre jug and the pour the smoothie mixture on top. Next pour in the Goslings Black Seal Rum and stir well. Finally top with the Prosecco Serve with one large ice cube in a single rocks glass and garnish with a mint sprig Perfectly Pink Punch (Serves 6-8) 200ml Bathtub Gin 150ml raspberry cordial 150ml freshly squeezed lemon juice (about 3-4 lemons) 100ml agave syrup (optional, adjust to taste) 500ml sparkling water or soda water, chilled Fresh raspberries for garnish Lemon slices for garnish Ice cubes Method: In a punch bowl or jug, combine the Bathtub Gin, raspberry cordial, agave syrup, and freshly squeezed lemon juice. Stir well to ensure all ingredients are fully mixed. Chill the punch in the refrigerator for at least 1 hour to allow the flavours to meld together. Desi Mango Spritz 25ml Desi Daru Alphonso Mango Vodka 25ml Sauvignon Blanc 100ml London Essence Co Peach & Jasmine Soda Method: Build over ice in a wine glass. Stir gently and garnish with a curry leaf.
Yahoo
12-06-2025
- Business
- Yahoo
Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav®
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is one of the 13 Biotech Stocks with Huge Upside Potential. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is one of the stocks with the biggest upside. It presented late-breaking Phase 4 data on Xywav® at SLEEP 2025, which included findings from the XYLO and DUET trials. A biopharmaceutical scientist in their lab, studying a newly-diagnosed therapy-related acute myeloid leukemia. . In the XYLO study (n=43), moving from high-sodium to low-sodium oxybate resulted in a substantial decrease in 24-hour ambulatory systolic blood pressure (−4.1 mmHg; P=0.0019). SBP reduction during the day (−5.1 mmHg; P=0.0003) and while seated (−9.2 mmHg; P<0.0001) were secondary objectives. The TEAEs were moderate or mild. DUET data from 24 subjects taking 9-12g Xywav nightly displayed improvement in excessive daytime sleepiness and narcolepsy severity with an average dose of 11.2g during the stable period. Xywav is the sole FDA-approved low-sodium oxybate for cataplexy or EDS in narcolepsy and idiopathic hypersomnia. Xywav reduces nightly sodium intake by up to 92% compared to Xyrem®, lowering cardiovascular risk, which is a serious issue in narcolepsy patients. Both indications were awarded Orphan Drug Exclusivity by the FDA. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)'s data underscores how crucial it is to lower sodium intake in long-term sleep disorder treatment plans. While we acknowledge the potential of JAZZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
10-06-2025
- Business
- Business Insider
Jazz Pharmaceuticals presents late-breaking phase 4 data showcasing Xywav
Jazz Pharmaceuticals (JAZZ) 'announced late-breaking Phase 4 data evaluating treatment benefits of Xywav oral solution in people with narcolepsy. These results are two of Jazz's four late-breaking abstracts presented today as oral presentations at SLEEP 2025. The four late-breaking abstracts, selected for their scientific quality and innovation, comprise all industry-sponsored late-breaking oral presentations selected by the Associated Professional Sleep Societies. Xywav is the only low-sodium oxybate approved by the U.S. Food and Drug Administration for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy and for adults with idiopathic hypersomnia. The Xywav label recommends a nightly dose of 6-9 grams per night.' Confident Investing Starts Here:
Yahoo
20-05-2025
- Business
- Yahoo
JAZZ Q1 Earnings Call: Revenue and Profit Miss, Product Pipeline Drives Outlook
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) fell short of the market's revenue expectations in Q1 CY2025, with sales flat year on year at $897.8 million. On the other hand, the company's outlook for the full year was close to analysts' estimates with revenue guided to $4.28 billion at the midpoint. Its non-GAAP profit of $1.68 per share was 63.9% below analysts' consensus estimates. Is now the time to buy JAZZ? Find out in our full research report (it's free). Revenue: $897.8 million vs analyst estimates of $986.6 million (flat year on year, 9% miss) Adjusted EPS: $1.68 vs analyst expectations of $4.66 (63.9% miss) Adjusted EBITDA: $206.5 million vs analyst estimates of $399.6 million (23% margin, 48.3% miss) The company reconfirmed its revenue guidance for the full year of $4.28 billion at the midpoint Management lowered its full-year Adjusted EPS guidance to $4.80 at the midpoint, a 79.4% decrease Operating Margin: -6.2%, down from 7.3% in the same quarter last year Free Cash Flow Margin: 46.3%, up from 28.9% in the same quarter last year Market Capitalization: $6.72 billion Jazz Pharmaceuticals' first quarter results reflected a flat revenue performance and significant shortfall on non-GAAP earnings relative to Wall Street expectations. Management attributed this outcome primarily to strong demand in the neuroscience portfolio, particularly Xywav and Epidiolex, which offset near-term headwinds in oncology products such as Rylaze and Zepzelca. CEO Bruce Cozadd highlighted execution on commercial efforts, stating the company remains 'confident in the blockbuster potential' of Epidiolex and is seeing 'continued momentum' for Xywav, especially in idiopathic hypersomnia. For the remainder of the year, management's guidance is anchored by anticipated regulatory milestones and commercial launches in oncology. The company's strategy includes leveraging recent acquisitions, such as Chimerix, to expand its rare oncology presence and prepare for upcoming product launches like Dordaviprone. Management also addressed ongoing litigation settlements and tariff risks, noting that inventory planning and flexible manufacturing are expected to minimize impacts for 2025. Jazz Pharmaceuticals' Q1 performance was shaped by mixed trends across its portfolio, with neuroscience products showing growth and oncology products experiencing headwinds. Several strategic actions—including a major acquisition and regulatory filings—also influenced the quarter's results and future positioning. Neuroscience Portfolio Growth: Xywav and Epidiolex led revenue growth, with Xywav patient additions driven by targeted disease education campaigns and Epidiolex benefiting from expanded use in adult and long-term care settings. Management emphasized Xywav's status as the only FDA-approved therapy for idiopathic hypersomnia, supporting market expansion. Oncology Pressure and Pipeline: The oncology portfolio saw declines, primarily due to protocol changes affecting Rylaze and competitive dynamics for Zepzelca. Management expects normalization of Rylaze revenue and highlighted upcoming data presentations for Zepzelca's first-line use, which could shift its growth trajectory if included in treatment guidelines. Chimerix Acquisition and Dordaviprone Launch: The acquisition of Chimerix added Dordaviprone, a therapy for rare brain tumors, to the pipeline. Management described Dordaviprone as a "meaningful and durable revenue opportunity" due to its potential frontline use and patent protection into 2037. Supply Chain and Tariff Preparedness: Jazz outlined its extensive manufacturing footprint in the U.S. and Europe, noting that diversified supply and inventory management should mitigate the impact of enacted and potential tariffs for the rest of the year. Strategic R&D Progress: Multiple regulatory milestones are on the horizon, including FDA and European reviews for new oncology indications. Upcoming data from pivotal trials in HER2-positive cancers and the anticipated launch of Dordaviprone are expected to be key product catalysts. Looking ahead, Jazz's guidance relies on continued neuroscience portfolio growth and the successful advancement of its oncology pipeline, while also navigating cost pressures and regulatory developments. Oncology Regulatory Milestones: Management believes that data readouts and regulatory decisions for products like Dordaviprone and zanidatamab will be critical to expanding the oncology business and supporting revenue growth. Neuroscience Market Expansion: The company expects further demand for Xywav, especially in idiopathic hypersomnia, to drive patient growth, while Epidiolex is positioned to achieve blockbuster status through expanded indications and access initiatives. Tariff and Litigation Risks: While management downplayed tariff impacts for 2025 due to inventory and manufacturing flexibility, future regulatory changes or litigation expenses remain uncertainties that could affect margins and adjusted earnings. Jason Gerberry (Bank of America): Asked about Xywav's supply chain resilience if tariffs escalate, with management confirming U.S. manufacturing capacity can supply the domestic market and minimize tariff risk. Jessica Fye (JP Morgan): Inquired about Jazz's overall manufacturing footprint and contingency plans for biopharma tariffs, with management highlighting geographic diversification and a strategy of building U.S. inventory. David Amsellem (Piper Sandler): Questioned the long-term outlook for Zepzelca in the face of new competition, with executives citing upcoming first-line data as potentially expanding its patient base and duration of therapy. Annabel Samimy (Stifel): Sought updates on Rylaze's adoption in adolescent and young adult segments, with management acknowledging slow but steady momentum and confidence in normalization by next quarter. Joseph Thome (TD Cowen): Asked about Dordaviprone's Phase III trial status and regulatory review, with Jazz noting ongoing enrollment outside the U.S. and no current issues with the FDA review timeline. In the coming quarters, the StockStory team will watch for (1) pivotal data releases for zanidatamab in HER2-positive gastroesophageal cancer, (2) the FDA's decision on Dordaviprone and progress in its confirmatory frontline trial, and (3) signs of sustained growth in Xywav and Epidiolex patient populations. Successful integration of Chimerix and the impact of evolving tariff policies will also be important to monitor as the year progresses. Jazz Pharmaceuticals currently trades at a forward P/E ratio of 4.7×. Should you load up, cash out, or stay put? See for yourself in our free research report. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
